C urrently, 52 human adenovirus serotypes have been described (1) . They are commonly isolated from clinical specimens and often show a seasonal pattern in temperate countries similar to the influenza virus (2, 3) . Adenoviral infections of the lower respiratory tract are rarely associated with long-term pulmonary aftermaths such as bronchiolitis obliterans and bronchiectasis (4) . These viruses can be a threat to severely immunocompromised patients, either by primary infection or endogenous reactivation. In such patients, they often lead to high morbidity and mortality (1) . As with many other adenoviruses, the adenovirus type 3 strain has been involved in community and nosocomial outbreaks (5, 6) . Cases of severe and fatal pneumonia have been related to the adenovirus type 3 strain in both immunocompromised and previously healthy hosts (7) (8) (9) .
case presentation
A province-wide outbreak of adenovirus type 3 that occurred during a five-month period (fall of 2008 to the winter of 2009) is described. The medical microbiology laboratory of the Centre hospitalier universitaire Dr-Georges-L-Dumont (Moncton, New Brunswick) receives more than 800 specimens annually for respiratory viral cultures. Being the only laboratory offering viral cultures in New Brunswick, the data give important epidemiological information on current viral threats in the community (population estimation of 747,300 individuals). Clinical samples for respiratory viruses are inoculated following the same protocol that has been used in the laboratory since 1993. Briefly, the supernatant from each sample is inoculated in one flat-bottom tube containing in-house prepared Madin-Darby canine kidney cells and human lung adenocarcinoma cells (A549) in buffered minimal essential medium (MP Biomedicals LLC, USA) without fetal bovine serum.
Bovine albumin, D-glucose, trypsin, gentamicin, vancomycin and amphotericin B are added to the tubes, which are centrifuged at 1600 g for 60 min at 33°C and then held for one week at 33°C in 5% CO 2 and observed for a cytopathic effect (CPE). An immunofluorescence assay is performed once the CPE is observed (Light Diagnostics Respiratory Panel I Viral Screening and Identification IFA, Millipore, USA). Samples showing no obvious CPE at the end of the incubation period are also submitted for immunofluorescence testing using the same assay. cultures excluded). The sources of the specimens were the following: 43% nasopharyngeal, 24% unspecified, 22% stool, 7% ocular, 2% urine and 2% bronchial. Adenoviruses were isolated in 15% of the total respiratory viral cultures requested during that period. Cases were distributed in the province according to the federal electoral districts: Acadie-Bathurst (two cases), Beauséjour (two cases), Fredericton (two cases), Fundy-Royal (no cases), Madawaska-Restigouche (one case), Miramichi (no cases), Moncton-Riverview-Dieppe (31 cases), Saint-John (four cases), South-West (no cases) and Tobique-Mactaquac (no cases). Age group distribution was as follows: five years or younger (22 cases), six to 12 years (10 cases), 13 to 18 years (no cases), and 19 years or older (10 cases). The majority of patients were female (60%). The provincial Communicable Disease Control Unit was notified and a province-wide notice was rapidly broadcasted. Seventeen viral strains were sent to the National Microbiology Laboratory in Winnipeg, Manitoba, for partial hexon gene sequencing, as previously described (10); sequencing showed that they all belonged to the adenovirus type 3 strain. During this outbreak, and to the authors' best knowledge, three cases of severe adenovirus pneumonia were reported (individuals between 33 and 40 years of age, all immunocompetent male patients, and all hospitalized). Two were confirmed by positive culture. The third patient seroconverted toward adenovirus (fourfold increment in complement fixation titre); the throat viral culture was negative. Of these three cases, one was fatal. A 40-year-old man was admitted to the Centre hospitalier universitaire Dr-Georges-LDumont on January 2, 2009, and initially presented with a flu-like illness, shaking chills, shortness of breath and productive cough. He was known to be epileptic and to have sleep apnea, for which he underwent a uvuloplasty. Table 1 shows the patient's paraclinical data during hospitalization. An initial chest x-ray showed ill-defined bilateral lower lobe infiltrations that progressed rapidly toward a frank right lower lobe consolidation on day 3. He was initially treated for community-acquired pneumonia with antibiotics (cefuroxime and moxifloxacin). Bronchoscopy was performed on day 6. Bronchial washing and tracheal aspirate cultures performed while he was on antibiotics showed normal oropharyngeal flora; polymerase chain reaction for influenza, Legionella urinary antigen test and cold agglutinins blood test were negative. On day 8, his condition suddenly deteriorated and he was intubated. Chest computed tomodensitometry revealed bilateral patchy ground-glass opacifications and consolidation of both lower lobes with pleural effusions. On the ninth day of hospitalization, 72 h viral cultures from the bronchial washing showed a typical adenovirus CPE on A549 cells, which was confirmed by indirect immunofluorescence assay. Cidofovir (1 mg/kg) with probenecid was started immediately. He received a second dose of cidofovir (3 mg/kg) with probenecid on day 11. He also received 400 mg/kg of intravenous pooled gammaglobulins (Gammagard liquid, Baxter Healthcare Corporation). His condition improved transitorily. He remained febrile throughout his hospitalization, with spiking fevers above 39°C. His health rapidly declined five days after starting cidofovir with multiple organ failure and intractable acute respiratory distress syndrome leading to death. Sera collected on day 6 and day 12 showed seroconversion toward adenovirus with an acute serum titre of 1:64 and a late serum titre higher than 1:256 (complement fixation). An autopsy was not performed, as requested by his family.
DiscUssion
The described outbreak and present case report illustrates some important issues concerning adenovirus pneumonia. First, the adenovirus type 3 strain is one of the most prevalent types of adenovirus strains detected globally (11) . The adenovirus type 3 strain seems to be the predominant virus serotype isolated in Canada (Y Li, personal communication). At the onset of this outbreak and because of the severity of the three cases reported here, a recently described highly virulent and pneumotropic adenovirus type 14 strain was first suspected (12, 13) . Partial hexon gene sequencing revealed it to be the adenovirus type 3 strain. This province-wide outbreak may reflect recently observed outbreaks related to the adenovirus type 3 strain, in which a new virulent subgenomic variant (adenovirus type 3a50 strain) was described (9, 11) . Adenovirus spreads rapidly in a community, with higher attack rates related to crowding of susceptible hosts (14) . This experience shows an epidemic spread of an adenoviral strain that swept the province during a very short period. One patient who initially presented with community-acquired pneumonia had a fatal outcome, despite treatment aimed at the adenovirus. Barring that no autopsy was performed to definitely prove adenovirus pneumonia as the cause of death, the adenovirus type 3 strain was the sole pathogen isolated in this patient who subsequently seroconverted. Heightened clinical suspicion is important once an adenovirus outbreak is known to occur. Conjunctivitis, high fever with shaking chills, lobar pneumonia not responding to antibiotics or rapidly progressing, leukocytosis, hypoxemia and multiple organ failure are many elements that can suggest adenovirus pneumonia. Without viral respiratory culture or targeted/multiplex polymerase chain reaction, this case would have been missed. Severe cases often show an unpredictable and rapidly downhill deterioration toward death despite aggressive treatment, 
